CR9112792, a Follow-up of Study CR9108963

Osteoporosis Clinical Trial

Official title:

Study CR9112792, a Study to Assess Bone Mineral Density Changes in Post-menopausal Osteoporotic Women Following Discontinuation of Ronacaleret or Placebo Treatment in Study CR9108963

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00891553
• Other study ID #: 112792
• Status: Completed
• Phase: N/A
• First received: April 23, 2009
• Last updated: February 21, 2013
• Start date: March 2009
• Est. completion date: June 2009

Study information

• Verified date: February 2013
• Source: GlaxoSmithKline
• Contact: n/a
• Is FDA regulated: No
• Health authority: Argentina: Ministry of Health - A.N.M.A.TNorway: Statens LegemiddelverkDenmark: LægemiddelstyrelsenHong Kong: Department of HealthSouth Africa: Medicines Control CouncilPoland: URZ.D REJESTRACJI PRODUKTÓW LECZNICZYCH, WYROBÓW MEDYCZNYCH I PRODUKTÓW BIOBÓJCZYCH,CEBKUnited States: Food and Drug AdministrationAustralia: Therapeutic Goods Administration
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to determine whether bone mineral density has increased in a subgroup of postmenopausal osteoporotic women from study CR9108963, between 6 and 12 months following cessation of ronacaleret therapy.

Description:

CR9112792 is a follow-up study of CR9108963, the 12 month dose ranging study of ronacaleret (SB-751689), a calcium sensing receptor antagonist, in postmenopausal women with osteoporosis. CR9108963 evaluated the effects of ronacaleret (100mg, 200mg, 300mg, 400mg) on bone mineral density (BMD), safety and tolerability in comparison with placebo and 2 active comparators, alendronate and teriparatide. CR9108963 was terminated earlier than planned due to an observed lack of efficacy in lumbar spine and hip BMD. In this study we will follow-up subjects between 6 and 12 months after they discontinued treatment with ronacaleret to evaluate the potential for mineralization of bone following cessation of ronacaleret therapy. Subjects at pre-specified sites from the CR9108963 placebo, 200mg, 300mg and 400mg dose groups will be included in this study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 171
• Est. completion date: June 2009
• Est. primary completion date: June 2009
• Accepts healthy volunteers: No
• Gender: Female
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Informed consent: Subject is willing and able to provide written informed consent.

• Subjects: Subjects must have completed through the Month 12 visit of study CR9108963, or have had an early withdrawal visit on or after their Month 10 visit.

• DXA: Subjects must have either a final evaluable spine or hip DXA scan in CR9108963 as confirmed by Synarc, taken within 4 weeks of the last dose of study medication.

• Study medication: Subjects must have been on placebo or ronacaleret 200mg, 300mg or 400mg for =299 days in study CR9108963.

Exclusion Criteria:

• Any treatment with a PTH-based therapy or strontium ranelate after discontinuation of treatment in study CR9108963.

• Chronic systemic corticosteroid [e.g., glucocorticoid, mineralocorticoid] treatment of more than 2 intra-articular injections within the past year or use of oral, parenteral, or long-term, high-dose inhaled corticosteroids. Treatment with any topical corticosteroid will not exclude the subject from participating.

• Treatment with any topical corticosteroid will not exclude the subject from participation.

• Treatment with fluoride (dose greater than 10mg/day) for osteoporosis after discontinuation of treatment in study CR9108963.

• Administration of any investigational drug after discontinuation of treatment in study CR9108963.

• Subject who, in the opinion of the investigator, is unfit for this study or unable to comply with the requirements of the protocol.

Study Design

Time Perspective: Prospective

Related Conditions & MeSH terms

• Osteoporosis

Intervention

Procedure:
• DXA
CR9112792 is a follow-up study of CR9108963, in which the effects of ronacaleret (100mg, 200mg, 300mg, 400mg) on bone mineral density (BMD), safety and tolerability were evaluated in comparison with placebo and 2 active comparators, alendronate and teriparatide. In this study we will follow-up subjects between 6 and 12 months after they discontinued treatment with placebo or ronacaleret (200mg, 300mg, 400mg) to evaluate the potential for mineralization of bone following cessation of ronacaleret therapy, evaluating lumbar spine and hip BMD by DXA. There is no administration of drug in this study.

Locations

Country	Name	City	State
Denmark	GSK Investigational Site	Ballerup
Norway	GSK Investigational Site	Bergen
Norway	GSK Investigational Site	Hamar

Sponsors (1)

Lead Sponsor	Collaborator
GlaxoSmithKline

Countries where clinical trial is conducted

Denmark,  Norway, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percent change in BMD, as measured by DXA, at the lumbar spine (L1-L4)		6 to 12 months from the final CR9108963 DXA to the CR9112792 study visit	No
Secondary	Percent change in BMD, as measured by DXA, at the total hip, trochanter and femoral neck		6 to 12 months from the final CR9108963 DXA to the CR9112792 study visit	No
Secondary	Percent change in BMD, as measured by DXA, at the lumbar spine (L1-L4) and total hip, trochanter and femoral neck		16 to 25 months from the screening CR9108963 DXA to the CR9112792 study visit	No
Secondary	Percent change in BMD, as measured by DXA, at the lumbar spine (L1-L4) and total hip, trochanter and femoral neck		12 to 18 months from the month 6 CR9108963 DXA to the CR9112792 study visit	No